The failure of a clinical trial by biotech firm Opthea has caused shares in its backer Regal Partners to decline 52 per cent year-to-date and hit its funds under manageme...
Despite concerns that the popularity of pharmaceutical drug Ozempic is overblown, two fund managers are seeing stock picking opportunities from its success. ...
Global healthcare stocks are expected to perform strongly over the long term thanks to a huge boost in healthcare spending across developing and developed economies trigg...
Global fund managers are becoming more defensive in their asset allocation, according to Bank of America Merrill Lynch, as they adjust to the geopolitical environment. ...
Significant ethical issues there. If a relationship is in the process of breaking down then both parties are likely to b...
It's not licensees not putting them on, it's small businesses (that are licensed) that cannot afford to put them on. The...
So we are now underwriting criminal scams?...